США - англійська - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - leflunomide (unii: g162gk9u4w) (leflunomide - unii:g162gk9u4w) - leflunomide 10 mg - leflunomide tablets usp are indicated for the treatment of adults with active rheumatoid arthritis (ra).  leflunomide is contraindicated in: ·            pregnant women. leflunomide may cause fetal harm. if a woman becomes pregnant while taking this drug, stop leflunomide, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure [see warnings and precautions (5.1 and 5.3) and use in specific populations (8.1)].   ·            patients with severe hepatic impairment [see warnings and precautions (5.2)]. ·            patients with known hypersensitivity to leflunomide or any of the other components of leflunomide. known reactions include anaphylaxis [see adverse reactions (6.1)]. ·             patients being treated with teriflunomide [see drug interactions (7)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to leflunomide during pregnancy. health care providers and patients are encouraged to report pr

США - англійська - NLM (National Library of Medicine)

alembic pharmaceuticals limited - leflunomide (unii: g162gk9u4w) (leflunomide - unii:g162gk9u4w) - leflunomide 10 mg - leflunomide tablets usp are indicated for the treatment of adults with active rheumatoid arthritis (ra).  leflunomide is contraindicated in: ·            pregnant women. leflunomide may cause fetal harm. if a woman becomes pregnant while taking this drug, stop leflunomide, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure [see warnings and precautions (5.1 and 5.3) and use in specific populations (8.1)].   ·            patients with severe hepatic impairment [see warnings and precautions (5.2)]. ·            patients with known hypersensitivity to leflunomide or any of the other components of leflunomide. known reactions include anaphylaxis [see adverse reactions (6.1)]. ·             patients being treated with teriflunomide [see drug interactions (7)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to leflunomide during pregnancy. health care providers and patients are encouraged to report pr

США - англійська - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - leflunomide (unii: g162gk9u4w) (leflunomide - unii:g162gk9u4w) - leflunomide 10 mg - leflunomide tablets, usp are indicated for the treatment of adults with active rheumatoid arthritis (ra). leflunomide tablets are contraindicated in: •pregnant women.  leflunomide may cause fetal harm.  if a woman becomes pregnant while taking this drug, stop leflunomide, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure [see warnings and precautions (5.1and 5.3) and use in specific populations (8.1)]. •patients with severe hepatic impairment [see warnings and precautions (5.2)] . •patients with known hypersensitivity to leflunomide or any of the other components of leflunomide tablets. known reactions include anaphylaxis [see adverse reactions (6.1)] . •patients being treated with teriflunomide [see drug interactions (7)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to leflunomide during pregnancy.  health care providers and patients are encouraged to report pregnancies by calling 1-877-3

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - leflunomide -

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - leflunomide -

Європейський Союз - англійська - EMA (European Medicines Agency)

medac gesellschaft für klinische spezialpräparate mbh - leflunomide - arthritis, rheumatoid - selective immunosuppressants - leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (dmard).recent or concurrent treatment with hepatotoxic or haematotoxic dmards (e.g. methotrexate) may result in an increased risk of serious adverse reactions, therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.moreover, switching from leflunomide to another dmard without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.

Європейський Союз - англійська - EMA (European Medicines Agency)

ratiopharm gmbh - leflunomide - arthritis, rheumatoid - immunosuppressants - leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (dmard);active psoriatic arthritis.recent or concurrent treatment with hepatotoxic or haematotoxic dmards (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.moreover, switching from leflunomide to another dmard without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching.

Австралія - англійська - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - leflunomide -